Aims. To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine t wice daily and latanoprost once daily in primary open angl...
详细信息
Aims. To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine t wice daily and latanoprost once daily in primary open angle glaucoma or ocular hypertensive subjects. Methods. A prospective, double masked, active controlle d comparison in which qualified subjects had all glaucoma medicines discontinued for 1 month and then were randomized to either LTFC or brimonidine and latanopr ost concomitant therapy for 6 weeks. They were then switched to the other treatm ent regimen. The intraocular pressure (IOP) was measured at 0800, 1200, and 1600 h at baseline and at the end of Periods 1 and Period 2. Results. In 32 subjects , the diurnal curve of the untreated IOP of 26.0±3.4 decreased to 17.8±2.5 on LTFC and 17.2±2.8 mmHg on brimonidine and latanoprost (P=0.31). At 0800 and 160 0 h, the IOPs were statistically similar between the groups (P > 0.05). At 1200 h the latanoprost and brimonidine treatment IOP was statistically lower (16.2±3 .2) than LTFC (18.0±2.8 mmHg). However, the reduced IOP from untreated baseline was not statistically different at each time point and for the diurnal curve fo r each therapy (P groups for both solicited and unsolicited side effects (P > 0.05). Conclusion. This study suggests that LT FC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline.
Background Imatinib is approved worldwide for use in gastrointestinal stromal tumours (gIST).We aimed to assess dose dependency of response and progression-f ree survival with imatinib for metastatic gIST. Methods 946...
详细信息
Background Imatinib is approved worldwide for use in gastrointestinal stromal tumours (gIST).We aimed to assess dose dependency of response and progression-f ree survival with imatinib for metastatic gIST. Methods 946 patients were random ly allocated imatinib 400 mg either once or twice a day. Those assigned the once a day regimen who had progression were offered the option of crossover. The pri mary endpoint was progression-free survival. Analysis was by intention to treat . Findings At median follow-up of 760 days (IQR 644-859), 263 (56%) of 473 pa tients allocated imatinib once a day had progressed compared with 235 (50%) of 473 who were assigned treatment twice a day (estimated hazard ratio 0.82 >; p=0.026). Side-effects arose in 465/470 (99%) patients allocated the once daily regimen compared with 468/472 (99%) assigned treatment twice a day. By comparison with the group treated once a day, more dose reductions (77 > vs 282 >) and treatment interruptions (189 > vs 302 >) were recorded in patients allocated the twice daily regimen, but treatment in both a rms was fairly well tolerated. 52 (5%) patients achieved a complete response, 4 42 (47%) a partial response, and 300 (32%) stable disease, with no difference between groups. Median time to best response was 107 days (IQR 58-172). Interpr etation If response induction is the only aim of treatment, a daily dose of 400 mg of imatinib is sufficient; however, a dose of 400 mg twice a day achieves sig nificantly longer progression-free survival.
暂无评论